SynthesisBMC gastroenterology2026

Is PD-1/PD-L1 inhibitor plus bevacizumab superior to sorafenib as first-line treatment for advanced hepatocellular carcinoma? A pooled analysis of four phase 3 RCTs.

Qisheng Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.